DAVID J. MACK - 31 Jan 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Director
Signature
/s/ Javier Rodriguez, Attorney-in-Fact for David J. Mack
Issuer symbol
BTAI
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
04 Feb 2025, 17:28:36 UTC
Previous filing
03 Jan 2025
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise +27,089 +50% 81,267 31 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Options Exercise $0 -27,089 -10% $0.000000 243,810 31 Jan 2025 Common Stock 27,089 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.